[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pluto Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100622971","phase-2-a-study-of-plh-2301-in-subjects-with-sarcopenia-100622971",false,"NCT07390552","A Study of PLH-2301 in Subjects With Sarcopenia","A Prospective, Randomized, Double-blinded, Placebo-controlled, 4-Parallel Arm, Multi-center, Phase 2 Trial to Evaluate Efficacy and Safety of Orally Administered PLH-2301 in Elderly Patients With Sarcopenia","PLH-2301_P2","Inclusion Criteria:\n\n* Male or female subjects aged 65 years or older at the time of consent\n* Diagnosis of sarcopenia based on predefined diagnostic criteria\n* Short Physical Performance Battery (SPPB) total score within the protocol-defined range at screening\n* Stable body weight for at least 3 months prior to screening\n* Able to walk independently with or without assistive devices\n* Willing and able to comply with study procedures\n* Provided written informed consent prior to any study-specific procedures\n\nExclusion Criteria:\n\n* History of clinically significant neuromuscular or musculoskeletal disorders that could affect muscle function\n* Uncontrolled cardiovascular, hepatic, renal, or metabolic disease\n* Use of medications known to affect muscle mass or function within the protocol-defined washout period\n* Participation in another interventional clinical trial within 3 months prior to screening\n* Any medical or psychiatric condition that, in the investigator's opinion, would interfere with study participation","ALL","65 Years",{"count":20,"type":21},168,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia.\n\nEligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks.\n\nThe primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.",[27],"Sarcopenia in Elderly",[29],"Sarcopenia","RECRUITING","2026-05-10",{"date":33,"type":34},"2026-05-12","ACTUAL",{"date":36,"type":34},"2026-05-08",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"Pluto Inc.","INDUSTRY",5,""]